We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+11.75%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.02B
AUM Growth
+$38.1M
Cap. Flow
+$21.6M
Cap. Flow %
2.1%
Top 10 Hldgs %
51.66%
Holding
52
New
9
Increased
9
Reduced
24
Closed
1

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.1M
2
MRUS
Merus
MRUS
+$27.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.3M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.7M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$14.2M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$87.2M
2
ARQL
Arqule Inc
ARQL
+$34.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.6M
4
ARRY
Array Biopharma Inc
ARRY
+$6.21M
5
RCUS icon
Arcus Biosciences
RCUS
+$4.86M

Sector Composition

Rank Sector Weight
1 Healthcare 83.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
51
Zymeworks
ZYME
$1.67B
$293K 0.03%
+19,804
New +$307K
OREX
52
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-534,900
Closed -$108K
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2018 Portfolio in Review

As of Q2 2018, BVF Inc held 52 positions worth $1.02B, up 3.9% from $986M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q2 2018 filing shows 9 new, 9 increased, 24 reduced and 1 closed positions. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M. The largest sale was Ironwood Pharmaceuticals, an estimated $87.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.

  • BVF Inc's largest Q2 2018 buy was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M.
  • BVF Inc added most to Merus in Q2 2018, an estimated $27.9M increase.
  • BVF Inc's biggest Q2 2018 reduction was Ironwood Pharmaceuticals, cutting an estimated $87.2M.
  • BVF Inc fully exited Orexigen Therapeutics, Inc. in Q2 2018, selling an estimated $108K.
  • BVF Inc's ten largest holdings make up 52% of its $1.02B portfolio in Q2 2018.
  • BVF Inc opened 9 new positions and closed 1 in Q2 2018.
  • BVF Inc's portfolio value rose 3.9% quarter-over-quarter to $1.02B.

Based on BVF Inc's 13F filing for Q2 2018, filed 14 Aug 2018.